Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 51Breast 6Gastrointestinal 5Tumor-Agnostic 4Thoracic 4CNS 4Head & Neck 3Gynecologic 2Sarcoma 1Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Endocrine 1Classical hematology 1

Conditions

Ovarian Neoplasms 2Recurrence 1

Interventions

Paclitaxel 268Carboplatin 264Cisplatin 194Bevacizumab 135pembrolizumab 99Surveys and Questionnaires 84Radiotherapy 77Cyclophosphamide 75olaparib 67Blood Specimen Collection 65Drug Therapy 62Hyperthermic Intraperitoneal Chemotherapy 60Gemcitabine 60niraparib 56Topotecan 56Brachytherapy 54liposomal doxorubicin 52Taxes 47Docetaxel 46Magnetic Resonance Spectroscopy 43Letrozole 36Cytoreduction Surgical Procedures 36Filgrastim 33Biopsy 33Surgical Procedures, Operative 32durvalumab 31Specimen Handling 31Doxorubicin 31Nivolumab 30Albumin-Bound Paclitaxel 28

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × cabazitaxel × Gynecologic × Clear all
NCT02560337 2020-10-08

CaTo-ROC

Vejle Hospital

Phase 2 Completed
26 enrolled
Gynecologic

Ovarian Neoplasms, Recurrence

NCT01747239 2014-12-04

Cabazitaxel in Platinum Refractory Ovarian Cancer

Vejle Hospital

Phase 2 Terminated
4 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡